Bionano Announces Publication from Institut Curie Showing Utility of OGM for Detection of HRD in Breast Cancer
11 Janeiro 2023 - 10:00AM
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the
publication of a study analyzing optical genome mapping (OGM) as a
method to identify homologous recombination deficiency (HRD) in
breast cancer samples. The study reported that OGM successfully
assessed levels of HRD in all samples, potentially improving
genomic profiling of solid tumor samples and offering an efficient,
lower-cost method of detecting HRD with greater sensitivity than
whole genome sequencing (WGS).
In the study, researchers at Institut Curie analyzed fifteen
retrospective HRD triple negative breast carcinoma samples
from the RadioPARP clinical trial investigating poly ADP ribose
polymerase (PARP) inhibitors to assess OGM’s ability to identify
HRD tumors, which are associated with a hyper-sensitivity to some
classes of drugs, in particular to PARP inhibitors. In this study,
OGM identified high numbers of tandem duplication and insertion
events and large-scale genomic alterations that are characteristic
of HRD, including subclonal variants missed by WGS. Though WGS is
commonly used for HRD detection, the study authors highlighted
challenges associated with using traditional methods and cited
OGM’s robust detection of large structural variants with a high
resolution, even in samples with low tumor content, as evidence of
its potential application as a first-line method in solid tumor
analysis for identification of HRD.
“This paper serves as a good demonstration of OGM’s utility for
assessing HRD, which is an emerging biomarker used to identify
patients who may respond to PARP inhibitors. We believe this study
shows that OGM can help overcome the limitations of traditional
methods and may capture greater numbers of genomic events
reflective of HRD, which we believe may translate into more
patients being qualified for life-saving treatments, such as PARP
inhibitors,” commented Erik Holmlin, PhD, president and chief
executive officer of Bionano Genomics.
This publication can be found here.
About Bionano Genomics
Bionano Genomics is a provider of genome analysis solutions that
can enable researchers and clinicians to reveal answers to
challenging questions in biology and medicine. The Company’s
mission is to transform the way the world sees the genome through
OGM solutions, diagnostic services and software. The Company offers
OGM solutions for applications across basic, translational and
clinical research. Through its Lineagen, Inc. d/b/a Bionano
Laboratories business, the Company also provides diagnostic testing
for patients with clinical presentations consistent with autism
spectrum disorder and other neurodevelopmental disabilities.
Through its BioDiscovery business, the Company also offers an
industry-leading, platform-agnostic software solution, which
integrates next-generation sequencing and microarray data designed
to provide analysis, visualization, interpretation and reporting of
copy number variants, single-nucleotide variants and absence of
heterozygosity across the genome in one consolidated view. For more
information, visit www.bionanogenomics.com,
www.bionanolaboratories.com or www.biodiscovery.com
Forward-Looking Statements of Bionano
Genomics
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “believe,” “can,” “may,” “potential” and
similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) convey
uncertainty of future events or outcomes and are intended to
identify these forward-looking statements. Forward-looking
statements include statements regarding our intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things, the ability and utility of OGM to detect tandem
duplications, insertions, and large-scale genomic alterations that
are characteristic of HRD in breast cancer samples; the ability and
utility of OGM to detect HRD in breast cancer samples; and the
ability and utility of OGM HRD detection to impact clinical
decision making. Each of these forward-looking statements involves
risks and uncertainties. Actual results or developments may differ
materially from those projected or implied in these forward-looking
statements. Factors that may cause such a difference include the
risks and uncertainties associated with: global and macroeconomic
events, such as the impact of the COVID-19 pandemic and the ongoing
Ukraine-Russian conflict and related sanctions, on our business and
the global economy; general market conditions; changes in the
competitive landscape and the introduction of competitive
technologies or improvements to existing technologies; failure of
OGM to detect tandem duplications, insertions, and large-scale
genomic alterations that are characteristic of HRD; failure of OGM
to improve genomic profiling of solid tumor samples through more
efficient and cost-effective detection of HRD in breast cancer
samples with greater sensitivity than whole genome sequencing
(WGS); future study results contradicting the results reported in
the publication referenced above; changes in our strategic and
commercial plans; our ability to obtain sufficient financing to
fund our strategic plans and commercialization efforts; the ability
of medical and research institutions to obtain funding to support
adoption or continued use of our technologies; and the risks and
uncertainties associated with our business and financial condition
in general, including the risks and uncertainties described in our
filings with the Securities and Exchange Commission, including,
without limitation, our Annual Report on Form 10-K for the year
ended December 31, 2021 and in other filings subsequently made by
us with the Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made and are based on management’s
assumptions and estimates as of such date. We do not undertake any
obligation to publicly update any forward-looking statements,
whether as a result of the receipt of new information, the
occurrence of future events or otherwise.
CONTACTSCompany Contact:Erik
Holmlin, CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionanogenomics.com
Investor Relations:Amy ConradJuniper Point+1
(858) 366-3243amy@juniper-point.com
Bionano Genomics (NASDAQ:BNGO)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Bionano Genomics (NASDAQ:BNGO)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024